Publicador de continguts

Recerca i Innovació Programes
Recerca

AiguaBCN

Exposure to emerging contaminants in drinking water in Barcelona potentially liked to chronic diseases and wellbeing

Projecte AiguaBCN
Durada
01/01/2020 - 30/06/2021
Coordinador
Cristina Villanueva Belmonte
Finançadors
Ajuntament de Barcelona, "la Caixa" Foundation
Pàgina web
https://www.barcelona.cat/barcelonaciencia/ca/pla-barcelona-ciencia/subvencions-extraordinaries-recerca-innovacio/projectes-subvencionats-convocatoria-2019/aiguabcn

Objectives

Drinking water may contain emerging contaminants related to chronic diseases and ageing. Through this study, we want to evaluate evaluate exposure to emerging pollutants in drinking water in Barcelona.

  • Measure perfluorinated substances (PFASs), bisphenol A (BPA), nonylphenol (NP), haloacetic acids (HAAs), chlorite and chlorate in drinking water.
  • Create a map of the concentrations in Barcelona;
  • Estimate the contribution of drinking water on the internal dose of PFASs and trichloroacetic acid;
  • Measure neurotoxicity in drinking water;
  • Quantify the contribution of PFASs, BPA, NP, HAAs, chlorite and chlorate on the in vitro neurotoxicity.

Methods

Descriptive study in Barcelona. 42 points (one per zip code) will be defined to take a sample of tap water. 10 samples of bottled water will be included, selecting the most popular brands, and 10 samples of filtered tap water (5 from reverse osmosis and 5 from filter jar).

The concentration of PFASs, BPA, NP, HAAs, chlorite and chlorate will be measured using sensitive methods based on chromatography and mass spectrometry.

Urine samples will be taken in 42 volunteers living in the homes sampled to measure PFASs and trichloroacetic acid, and the relative contribution of drinking water to urine levels will be estimated.

A generalized additive model will be applied to predict the level of PFASs, BPA, NP, HAAs, chlorite and chlorate at all points in Barcelona based on the levels measured.

In a subsample (N = 30) in vitro tests will be applied to estimate neurotoxicity in water samples using human neuroblastoma SH-SY5Y cells. The contribution of the different chemicals analyzed on each of the responses in vitro will be estimated using regression models.

AiguaBCN is a collaborative project led from ISGlobal in collaboration with IDAEA-CSIC (Dra. Cintia Flores, Dr. Josep Caixach, Dra. Marinella Farré), URV-Tecnatox (Dra. Marta Schuhmacher, Dr. Joaquim Rovira), ICRA (Dr. Maria José Farré), and UFZ (Dr. Beate Escher).

Impact

First complete information on exposure to emerging compounds in drinking water in Barcelona, with the potential to assess effects related to ageing in the population.

Total Funding

149.996,49 €

   

How to participate

Our Team

Coordinator

ISGlobal Team

Altres projectes

Veure projectes passats

MCC-Spain

Estudi multi-cas control poblacional, incloent tumors d'alta incidència a Espanya

HELIX

Novel tools for integrating early-life environmental exposures and child health across Europe

EGG/EAGLE

Early Genetics Growth/Early Genetics and Lifecourse Epidemiology

PACE

Pregnancy and Childhood Epigenetics

LIFECYCLE

Early-life stressors and LifeCycle health

OMEGA-NET

Network on the Coordination and Harmonisation of European Occupational Cohorts

HARMONIC

Health effects of cArdiac fluoRoscopy and mOdern radIotherapy in paediatriCs

Mobilise-D

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

EARLY-ADAPT

Signs of Early Adaptation to Climate Change

COVICAT

Cohorte Covid-19 en Cataluña

ATHLETE

Advancing Tools for Human Early Lifecourse Exposome Research and Translation

CONTENT

Cohort de COVID-19 a Espanya: dinàmica social, salut mental i desigualtats

EUCAN-Connect

A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized health

OBERON

An integrative strategy of testing systems for identification of EDs related to metabolic disorders

EXPANSE

EXposome Powered tools for healthy living in urbAN SEttings

AURORA 2021

Actionable eUropean ROadmap for early-life health Risk Assessment of micro- and nanoplastics

ONES

Fine Particle Matter, Fetal Growth, and Neurodevelopment: Examining Critical Windows of Susceptibility

AIR-NB

Pre-natal exposure to urban AIR pollution and pre- and post-Natal Brain development

NutinBrain

The role of seafood and nut consumption on human neurodevelopment from pregnancy to adolescence

UrbanKids

Urban and social environment and childhood obesity – a natural moving2health experiment

iGenCO

In-Depth Genomics and Cross-Omics Analysis for Undiagnosed Rare Diseases on a User-Friendly Collaborative Platform

CityExposomeCat

An Exposome Approach to Urban Health: Individualized Environmental Exposure Assessment in an Adults Population Cohort Study (GCAT)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

UBDPOLICY

The Urban Burden of Disease Estimation for POLICY Making

TOLIFE

Combining Artificial Intelligence and smart sensing TOward better management and improved quality of LIFE in chronic obstructive pulmonary disease

BWater

Drinking Water in Barcelona: Sustainability and Health Impact Assessment

intoDBP

Innovative Tools to Control Organic Matter and Disinfection Byproducts in Drinking Water

FINDOOR

FTIR spectroscopy for real-time detection of bacterial outbreaks and the rapid identification of pathogenic serotypes, relapsing infections and antibiotic resistance

OccRF-Health

Occupational exposure to radiofrequency electromagnetic fields: From exposure assessment to study of health in workers and their offspring

EPHOR

Exposome Project for Health and Occupational Research

EXPONIT

Analysing and studying how night shift work affects workers' circadian rhythms and health

IHEN

International Human Exposome Network

B-Triage

Una prueba en el punto de atención para la estratificación del riesgo de los pacientes febriles basada en los niveles de sTREM-1

e-QuoL

e-health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patients, survivors and their families